Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. II. Adjunctive therapy with R-hirudin

Journal of Cardiovascular Pharmacology

Volumn 2, Issue 2, 1994, Pages 203-211

  Rote, William E ^a   Mu, Dun Xue ^a   Bates, Eric R ^b   Nedelman, Mark A ^c   Lucchesi, Benedict R ^a  

^a Departments of Pharmacology   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c CENTOCOR INC   (United States)

Author keywords

Infarct Platelets; Recombinant tissue plasminogen activator Thrombin; Thrombosis

Indexed keywords

HIRUDIN;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOT LYSIS; BLOOD FLOW VELOCITY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY CIRCUMFLEX BRANCH; CORONARY ARTERY THROMBOSIS; DOG; DRUG EFFICACY; NONHUMAN; PRIORITY JOURNAL; RECURRENCE RISK; THROMBOGENESIS;

ANIMAL; BLOOD COAGULATION; CHRONIC DISEASE; CORONARY THROMBOSIS; CORONARY VESSELS; DOGS; FIBRINOLYTIC AGENTS; HIRUDIN THERAPY; MALE; MYOCARDIAL INFARCTION; PLATELET AGGREGATION; RECOMBINANT PROTEINS; RECURRENCE; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0027953552     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/00005344-199411000-00005     Document Type: Article

References (47)

1. Ridolfi RL, Hutchins GM. The relationship between coronary artery lesions and myocardial infarcts: Ulceration of atherosclerotic plaques precipitating coronary thrombosis. Am Heart J 1977;93:468-86.
2. Bovil EG, Becker R, Tracy RP. Monitoring thrombolytic therapy. Prog Cardiovasc Dis 1992;34:279-94.
3. Markwardt F. Past, present and future of hirudin. Haemostasis 1991;21(suppl I): 11-26.
4. Bang NU, Clayman MD. Antithrombotic agents from salivary glands of hematophagous animals. Trends Cardiovasc Med 1992;2:183-8.
5. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by hepa-rin-antithrombin III but is susceptible to inactivation by antithrombin Ill-independent inhibitors. J Clin Invest 1990;86:385-91.
6. Fuster V, Stein B, Badimon L, Chesebro JH. Antithrombotic therapy after myocardial reperfusion in acute myocardial infarction. J Am Coll Cardiol 1988;12:74A-84A.
7. Mruk JS, Chesebro JH, Webster MWI. Platelet aggregation and interaction with the coagulation system: Implications for antithrombotic therapy in arterial thrombosis. Coronary Artery Dis 1990;1:149-58.
8. Lee CD, Mann KG. Activation/inactivation of human factor V by plasmin. Blood 1989;73:185-90.
9. Francis CW, Markham RE, Barlow GH, Florack TM, Dobrzynski DM, Marder VJ. Thrombin activity of fibrin thrombi and soluble plasmin derivatives. J Lab Clin Med 1983;102:220-30.
10. Szczeklik A, Dropinski J, Radwan J, Krzanowski M. Persistent generation of thrombin after acute myocardial infarction. Atheroseler Thromb 1992;12:548-53.
11. Bates ER, Walsh DG1 Mu DX, Abrams GD, Lucchesi BR. Sustained inhibition of the vessel wall-platelet interaction after deep coronary artery injury by temporary inhibition of the platelet glycoprotein Ilb/IIIa receptor. Coronary Artery Dis 1992;3:67-76.
12. Mickelson JK, Simpson PJ, Lucchesi BR. Antiplatelet monoclonal F(ab')2 antibody directed against GPIIb/IIIa receptor complex prevents coronary artery thrombosis in the canine heart. J Mol Cell Cardiol 1989;21:393-405.
13. Mickelson JK, Simpson PJ, Cronin M, Homeister JW, Lay-well E, Lucchesi BR. Antiplatelet antibody [7E3 F(ab')2] prevents rethrombosis after recombinant tissue-type plami-nogen activator-induced coronary artery thrombolysis in a canine model. Circulation 1990;8:617-27.
14. Yasuda T, Gold HK, Yaoita H, et al. Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein Ilb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation. J Am Coll Cardiol 1990;16:714-22.
15. 2 fragments of the antiplatelet glycoprotein Ilb/IIIa antibody 7E3. Coronary Artery Dis 1991;2:1038-46.
16. Homeister JW, Mickelson JK, Hoff PT, Lucchesi BR. Recombinant hirudin reduces the incidence of thrombotic occlusion in a model of coronary vascular injury. Coronary Artery Dis 1991,2:237-46.
17. 2. J Cardiovas Pharmacol 1993;23:194-202.
18. Schumacher WA, Lee EC, Lucchesi BR. Augmentation of streptokinase-induced thrombolysis by heparin and prostacyclin. J Cardiovasc Pharmacol 1985;7:739-46.
19. Schaer DH, Ross AM, Wasserman AG. Reinfarction, recurrent angina and reocclusion after thrombolytic therapy. Circulation 1988;76(suppl II):II-57-62.
20. Harrison DG, Ferguson DW, Collins SM, et al. Rethrombo-sis after reperfusion with streptokinase: Importance of geometry of residual lesions. Circulation 1984;69:991-9.
21. Patterson E, Holland K, Eller BT, Lucchesi BR. Ventricular fibrillation resulting from ischemia at a site remote from previous myocardial infarction. A conscious canine model of sudden coronary death. Am J Cardiol 1982;50:1414-23.
22. Kimura S, Bassett AL, Saoudi NC, Cameron JS, Kozlovskis PL, Myergurg RJ. Cellular electrophysiologic changes and “arrhythmia ” during experimental ischemia and reperfusion in isolated cat ventricular myocardium. J Am Coll Cardiol 1986;7:833-42.
23. Della Grazia PM, Klugmann S, Morgera T, Salvi A, Pan-dullo C, Camerini F. Reperfusion ventricular arrhythmias during intracoronary thrombolysis. Eur Heart J 1986;7(suppl A):23-30.
24. Seitz R, Blanke H, Pratorious G, Stauer GE, Egbring R. Increased thrombin activity during thrombolysis [Letter]. Thromb Haemost 1988;59:541-2.
25. Fitzgerald DJ. Platelet activation in the pathogenesis of unstable angina: Importance in determining the response to plasminogen activators. Am J Cardiol 1991;68:51B-7B.
26. Gulba DC, Barthels M, Wetsthoff-Bleck M, et al. Increased thrombin levels during thrombolytic therapy in acute myocardial infarction: Relevance for the success of therapy. Circulation 1991;83:937-44.
27. Winters KJ, Santoro SA, Miletich JP, Eisenberg PR. Relative importance of thrombin compared with plasmin-mediated platelet activation in response to plasminogen activation with streptokinase. Circulation 1991;84:1552-60.
28. Weitz JI, Hirsh J. Antithrombins: Their potential as antithrombotic agents. Annu Rev Med 1992;43:9-16.
29. Jang I-K, Gold HK, Leinbach RC, et al. Persistent inhibition of arterial thrombosis by a 1-hour intravenous infusion of argatroban, a selective thrombin inhibitor. Coronary Artery Dis 1992;3:407-14.
30. Haskel EJ, Prager NA, Sobel BE, Abendschein DR. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion. Circulation 1991;83:1048-56.
31. Fareed J, Bacher P, Messmore HL, et al. Pharmacological modulation of fibrinolysis by antithrombotic and cardiovascular drugs. Prog Cardiovasc Dis 1992;34:379-98.
32. Kisiel W, Canfield WM, Ericsson LH, Davie EW. Anticoagulant properties of bovine plasma protein C following activation by thrombin. Biochemistry 1977;16:5824-31.
33. Vehar GA, Davie EW. Preparation and properties of bovine factor VIII (antihemophilic factor). Biochemistry 1980;19:401-10.
34. Hessing M. The interaction between complement component C4b-binding protein and the vitamin K-dependent protein S forms a link between blood coagulation and the complement system. Biochem J 1991;277:581-92.
35. Coller BS. Antiplatelet agents in the prevention and therapy of thrombosis. Annu Rev Med 1992;43:171-80.
36. Markwardt F. Hirudin and derivatives as anticoagulant agents. Thromb Haemost 1991;66:141-52.
37. Folts JD, Gallagher K, Rowe GG. Blood flow reductions in stenosed canine coronary arteries: Vasospasm or platelet aggregation? Circulation 1982;65:248-55.
38. Heras M, Chesebro JH, Webster MWI, et al. Hirudin, heparin, and placebo during deep arterial injury in the pig. The in vivo role of thrombin in platelet-mediated thrombosis. Circulation 1990;82:1476-84.
39. Yao SK, McNatt J, Anderson HV, et al. Thrombin inhibition enhances tissue-type plasminogen activator-induced thrombolysis and delays reocclusion. Am J Physiol 1992;262:H374-9.
40. Theroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992;327:141-5.
41. Hsia J, Kleiman N, Aguirre F, Chaitman BR, Roberts R, Ross AM, For the Heart Investigators. Heparin-induced prolongation of partial thromboplastin time after thrombolysis: Relation to coronary artery patency. J Am Coll Cardiol 1992;20:31-5.
42. Kander NH, Holland KJ, Pitt B, Topol EJ. A randomized pilot trial of brief versus prolonged heparin after successful reperfusion in acute myocardial infarction. Am J Cardiol 1990;65:139-42.
43. Eichhorn EJ, Graybum PA, Willard JE, et al. Spontaneous alterations in coronary blood flow before and after coronary angioplasty in patients with severe angina. J Am Coll Cardiol 1991;17:43-52.
44. Kwon K, Freedman SB, Wilcox I, et al. The unstable ST segment early after thrombolysis for acute infarction and its usefulness as a marker of recurrent coronary occlusion. Am J Cardiol 1991;67:109-15.
45. Folts J. Problems with platelet inhibitors of thrombus formation in stenosed coronary arteries [Abstract], J Am Coll Cardiol 1990;15:210A.
46. Nicolini FA, Rios G, Lee P, Kottke-Marchant K, Topol EJ. Inhibition of thrombin activity alone does not decrease the reocclusion rate following rt-PA-induced thrombolysis in canine coronary artery thrombosis [Abstract]. Throm Heo-most 1993;69:992.
47. Groves HM, Kinlough-Rathbone RL, Richardson M, et al. Platelet interaction with damaged rabbit aorta. Lab Invest 1979;40:194-200.